NeuroPhage to Present at 12th International Conference on Alzheimer’s & Parkinson’s Diseases
Cambridge, MA, March 16, 2015 – NeuroPhage Pharmaceuticals, Inc., today announced that Richard Fisher, PhD, the Company’s Chief Scientific Officer, will present at the 12th International Conference on Alzheimer’s & Parkinson’s Diseases, taking place March 18-22, 2015, in Nice, France. Dr. Fisher will present scientific data and clinical development plan update of the Company’s lead candidate, NPT088, which utilizes GAIM (general amyloid interaction motif) technology to simultaneously target multiple types of misfolded proteins found in many diseases of aging, such as Alzheimer’s and Parkinson’s diseases. His presentation, entitled “NPT088: A Drug Candidate that Targets Amyloid-beta, Tau and alpha-Synuclein Aggregates”, will take place Thursday, March 19 at 10:15am GMT.
NeuroPhage Pharmaceuticals, Inc. is a privately funded company headquartered in Cambridge, Massachusetts. NeuroPhage’s mission is to advance the treatment of misfolded protein diseases through GAIM therapy, simultaneously targeting multiple, toxic, misfolded proteins. NeuroPhage is initially developing drug candidates to treat Alzheimer’s and Parkinson’s diseases and several rare systemic amyloidosis diseases.